RUBY - ルビウス・セラピュ―ティクス (Rubius Therapeutics Inc.) ルビウス・セラピュ―ティクス

 RUBYのチャート


 RUBYの企業情報

symbol RUBY
会社名 Rubius Therapeutics Inc (ルビウス・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Rubius Therapeutics Inc is a biotechnology company that develops cellular therapies for cancer and enzyme deficiency diseases. The Company develops Red-Cell Therapeutics (RCT) products using red platform. RCT is a red blood cell-based therapy for applications in cancer enzyme replacement therapies and autoimmune disease and tolerance induction. Its RCT product candidate is designed to provide various attributes which include broad therapeutic applications predictable bio-distribution and advantageous tolerability. It is initially focused on advancing RCT product candidates for patients suffering from rare diseases cancer and autoimmune diseases based on three modalities - cellular shielding potent cell-cell interaction and tolerance induction. Its product candidates in rare diseases include RTX-134 for the treatment of phenylketonuria (PKU) RTX-134 followed by RTX-Uricase and RTX-CBS for the treatment of chronic refractory gout symptomatic homocystinuria.   ルビウス・セラピュ―ティクスは米国のバイオ医薬品企業。主に重症患者のための赤血球治療薬の開発に従事する。同社の候補薬はフェニルケトン尿症、ホモシスチン尿症、慢性不応性痛風、急性ポルフィリン症、固形腫瘍、血液がん、自己免疫疾患などの治療に使用される。本社所在地はマサチュ―セッツ州ケンブリッジ。   
本社所在地 325 Vassar Street Suite 1A Cambridge MA 02139 USA
代表者氏名 David R. Epstein David R. Epstein
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 617-679-9600
設立年月日 41365
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数 83人
url www.rubiustx.com
nasdaq_url https://www.nasdaq.com/symbol/ruby
adr_tso
EBITDA EBITDA(百万ドル) -72.29900
終値(lastsale) 17.01
時価総額(marketcap) 1344514677.03
時価総額 時価総額(百万ドル) 1354
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 1432.92
当期純利益 当期純利益(百万ドル) -73.79000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Rubius Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders increased from $15.1M to $44.4M. Higher net loss reflects Research and Development - Balancing increase from $7.3M to $19.9M (expense) Stock-based Compensation in SGA increase from $3.5M to $15.5M (expense) General and Administrative - Balancing increase from $1.9M to $6.6M (expense).

 RUBYのテクニカル分析


 RUBYのニュース

   The 2018 IPO Market's Most Active Venture Capital Firms  2018-12-22
88 companies went public in 2018 with venture capital backing. Excluding Spotify's (SPOT) direct listing, the group raised $15 billion in the IPO market. Venture exits accounted for 46% of 2018's total, and VC deal count and proceeds reached a 4-year high. The pickup in activity was driven by …

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ルビウス・セラピュ―ティクス RUBY Rubius Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)